

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1(Previously presented). An IFN- γ production inducing agent which consists essentially of an effective ingredient capable of inducing IFN- γ production by immunocompetent cells, said effective ingredient being an interferon-gamma (IFN- γ) production inducing protein, also known as IGIF and IL-18, having the following physicochemical properties:

- (1) Molecular weight
19,000 \pm 5,000 daltons on gel filtration and sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE);
- (2) Isoelectric point (pI)
4.8 \pm 1.0 on chromatofocusing; and
- (3) Biological activity
Inducing the interferon- γ production by immunocompetent cells.

2(Previously presented). A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and an effective ingredient capable of inducing IFN- γ production by immunocompetent cells, said effective ingredient being an

interferon-gamma (IFN- γ) production inducing protein, also known as IGIF and IL-18, having the following physicochemical properties:

- (1) Molecular weight
19,000 \pm 5,000 daltons on gel filtration and sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE);
- (2) Isoelectric point (pI)
4.8 \pm 1.0 on chromatofocusing; and
- (3) Biological activity
Inducing the interferon- γ production by immunocompetent cells.

3(Currently amended). A purified interferon-gamma (IFN- γ) production inducing protein, which is a variant of an interferon-gamma production inducing protein, also known as IGIF and IL-18, and which has the following physicochemical properties:

- (1) Molecular weight
19,000 \pm 5,000 daltons on gel filtration and sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE);
- (2) Isoelectric point (pI)
4.8 \pm 1.0 on chromatofocusing;

(3) Biological activity

Inducing the interferon- γ production by
immunocompetent cells; and

(4) Partial amino acid sequence

Possessing a part or the whole of the amino acid
sequence of SEQ ID NO:2, wherein the Xaa in SEQ ID
NO:2 is Met or Thr,

wherein said variant is a sequence variant of SEQ ID NO:2 which
corresponds to ~~[[an]]~~ the amino acid sequence of SEQ ID NO:2,
which is obtainable by replacing at least one amino acid residue
in SEQ ID NO:2 with a different amino acid residue or by deleting
or adding at least one amino acid residue in SEQ ID NO:2 ~~the N-~~
~~terminal region of~~ or to the N-terminus of SEQ ID NO:2 while not
substantially altering the above ~~physicochemical property~~
biological activity (3).

4(Previously presented). The purified protein
according to claim 3, wherein said variant has at least one amino
acid residue in SEQ ID NO:2 replaced with a different amino acid
residue.

5(Previously presented). The purified protein
according to claim 3, wherein said variant has at least one amino
acid residue deleted or added to the N-terminus of SEQ ID NO:2.

6(Previously presented). A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and, as an active ingredient, the protein of claim 3.

7(Previously presented). A purified interferon-gamma (IFN- γ) production inducing protein, also known as IGIF and IL-18, which has the amino acid sequence of SEQ ID NO:2, where Xaa represents methionine or threonine.

8(Previously presented). An interferon-gamma (IFN- γ) production inducing agent which consists essentially of, as an effective ingredient, the protein of claim 7.

9(Original). A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and, as an active ingredient, the protein of claim 7.

Claim 10 (Cancelled)

11(Currently amended). A purified interferon-gamma (IFN- γ) production inducing protein, also known as IGIF and IL-18, which has the following physicochemical properties:

(1) Molecular weight

19,000 \pm 5,000 daltons on gel filtration and sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE);

(2) Isoelectric point (pI)

4.8 ± 1.0 on chromatofocusing;

(3) Biological activity

Inducing the interferon-γ production by
immunocompetent cells; and

(4) Partial amino acid sequence

Possessing a part or the whole of the amino acid
sequence of SEQ ID NO:2, wherein the Xaa in SEQ ID
NO:2 is Met or Thr,

and which reacts with a monoclonal antibody specific to an
interferon-gamma (IFN-γ) production inducing protein having the
amino acid sequence of SEQ ID NO:2 or a sequence variant of the
protein having one or more of the [[same]] antigenic fragments
[[as in]] of the amino acid sequence of SEQ ID NO:2 while not
substantially altering the above biological activity (3).

Claims 12 and 13 (Cancelled)

14(Previously presented). A purified interferon-gamma
(IFN-γ) production inducing protein capable of inducing
interferon-gamma (IFN-γ) production by immunocompetent cells,
wherein said protein is encoded by a DNA sequence which
hybridizes to an oligonucleotide probe of SEQ ID NO:5 under the
hybridization conditions of 5 x SSPE, 5 x Denhardt's solution,

Appln. No.: 09/373,230
Amdt. dated June 7, 2004
Reply to Office Action of January 5, 2004

0.5 w/v% SDS, 100 µg/ml denatured salmon sperm DNA, and 45°C and after being washed with 6 x SSC.

15(Original). A pharmaceutical composition, comprising a pharmaceutically-acceptable carrier and, as an active ingredient, the protein of claim 14.

16(Previously presented). An isolated interferon-gamma (IFN-γ) production inducing protein, also known as IGIF and IL-18, which substantially retains its interferon-gamma (IFN-γ) production inducing activity even after treatment with SDS-PAGE.

17(Previously presented). A pharmaceutical composition, comprising a pharmaceutically-acceptable carrier and, as an active ingredient, the protein of claim 16.